Compare Ascendis Pharma A/S (ASND) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Kyndryl Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Kyndryl Holdings Inc trades at $12.36 (market cap $2.64B). The key difference: Ascendis Pharma A/S is far larger — about 6.7× Kyndryl Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | KD | |
|---|---|---|
Market Cap | $17.74B | $2.64B |
Sector | Health | Technology |
52-Week High | $277.18 | $39.78 |
52-Week Low | $163.32 | $10.59 |
Enterprise Value | $18.11B | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Kyndryl Holdings (KD) trades at $11.97, down 0.83% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $15.06B in 2025, achieving a net income of $252M after three years of losses. Recent news includes leadership changes and legal investigations, while analyst consensus is mixed with a $14.33 price target. Cash flow improved to a net positive $236M in 2025, though debt levels remain elevated.
The outlook is cautious; profitability improvements and strategic partnerships offer potential upside, but legal risks and recent earnings misses pose significant challenges. Investors should weigh the low P/E of 14.08 against ongoing operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
